Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Chemotherapy in Relapsed or Refractory Acute Lymphocytic Leukemia
NCT00002532Phase 2Unknown
- Sponsor
- Hannover Medical School
- Start
- Jan 1993
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cytarabine, etoposide and idarubicin in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Hannover Medical School. Primary endpoints: Toxic effects and feasibility and Response Rate. Status: unknown.
02
Drugs
cytarabineetoposideidarubicin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00002532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002532.